Abstract
Hepatocellular carcinoma (HCC) is a common tumor worldwide and a leading cause of tumor-related death. Surgical resection is one of the most effective treatments with curative potential. However, high recurrence rate (up to 50-70% in 5 years) after curative resection severely reduces the long-term survival of HCC patients. Especially, survival after resection of HCC in China liver cancer (CNLC) stage II-III remains poor. Anti-PD-1 antibody Camrelizumab combined with apatinib has been shown to be safe and effective in patients with advanced HCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
